Literature DB >> 22986424

"Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial.

Peter J Dyck, Carol J Overland, Phillip A Low, William J Litchy, Jenny L Davies, P James B Dyck, Rickey E Carter, L Joseph Melton, Henning Andersen, James W Albers, Charles F Bolton, John D England, Christopher J Klein, Gareth Llewelyn, Michelle L Mauermann, James W Russell, Dinesh Selvarajah, Wolfgang Singer, A Gordon Smith, Solomon Tesfaye, Adrian Vella.   

Abstract

OBJECTIVE To repeat the Clinical vs Neurophysiology (Cl vs N Phys) trial using "unequivocally abnormal" signs and symptoms (Trial 2) compared with the earlier trial (Trial 1), which used "usual" signs and symptoms. DESIGN Standard and referenced nerve conduction abnormalities were used in both Trials 1 and 2 as the standard criterion indicative of diabetic sensorimotor polyneuropathy. Physician proficiency (accuracy among evaluators) was compared between Trials 1 and 2. SETTING Academic medical centers in Canada, Denmark, England, and the United States. PARTICIPANTS Thirteen expert neuromuscular physicians. One expert was replaced in Trial 2. RESULTS The marked overreporting, especially of signs, in Trial 1 was avoided in Trial 2. Reproducibility of diagnosis between days 1 and 2 was significantly (P = .005) better in Trial 2. The correlation of the following clinical scores with composite nerve conduction measures spanning the range of normality and abnormality was improved in Trial 2: pinprick sensation (P = .03), decreased reflexes (P = .06), touch-pressure sensation (P = .06), and the sum of symptoms (P = .06). CONCLUSIONS The simple pretrial decision to use unequivocally abnormal signs and symptoms-taking age, sex, and physical variables into account-in making clinical judgments for the diagnosis of diabetic sensorimotor polyneuropathy (Trial 2) improves physician proficiency compared with use of usual elicitation of signs and symptoms (Trial 1); both compare to confirmed nerve conduction abnormality.

Entities:  

Year:  2012        PMID: 22986424      PMCID: PMC3570730          DOI: 10.1001/archneurol.2012.1481

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  DIABETIC NEUROPATHY: A METABOLIC OR A VASCULAR DISEASE?

Authors:  J PIRART
Journal:  Diabetes       Date:  1965-01       Impact factor: 9.461

Review 2.  Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

Authors:  J D England; G S Gronseth; G Franklin; R G Miller; A K Asbury; G T Carter; J A Cohen; M A Fisher; J F Howard; L J Kinsella; N Latov; R A Lewis; P A Low; A J Sumner
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

3.  Polyneuropathy dysfunction scores.

Authors:  P J Dyck; P C O'Brien
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-18       Impact factor: 10.154

4.  Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study.

Authors:  G M Franklin; L B Kahn; J Baxter; J A Marshall; R F Hamman
Journal:  Am J Epidemiol       Date:  1990-04       Impact factor: 4.897

5.  The Kristianstad survey. II. Studies in a representative adult diabetic population with special reference to comparison with an adequate control group.

Authors:  S V Nilsson; J E Nilsson; N Frostberg; T Emilsson
Journal:  Acta Med Scand Suppl       Date:  1967

6.  Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial.

Authors:  Peter J Dyck; Carol J Overland; Phillip A Low; William J Litchy; Jenny L Davies; P James B Dyck; Peter C O'Brien; James W Albers; Henning Andersen; Charles F Bolton; John D England; Christopher J Klein; J Gareth Llewelyn; Michelle L Mauermann; James W Russell; Wolfgang Singer; A Gordon Smith; Solomon Tesfaye; Adrian Vella
Journal:  Muscle Nerve       Date:  2010-08       Impact factor: 3.217

7.  The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests.

Authors:  P J Dyck; K M Kratz; K A Lehman; J L Karnes; L J Melton; P C O'Brien; W J Litchy; A J Windebank; B E Smith; P A Low
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

8.  Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy.

Authors:  Peter J Dyck; Rickey E Carter; William J Litchy
Journal:  Muscle Nerve       Date:  2011-09       Impact factor: 3.217

9.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

10.  Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry.

Authors:  P J Dyck; W R Sherman; L M Hallcher; F J Service; P C O'Brien; L A Grina; P J Palumbo; C J Swanson
Journal:  Ann Neurol       Date:  1980-12       Impact factor: 10.422

View more
  17 in total

Review 1.  Acquired neuropathies.

Authors:  Pierre Lozeron; Jean-Marc Trocello; Nathalie Kubis
Journal:  J Neurol       Date:  2013-06-16       Impact factor: 4.849

2.  Multicenter trial of the proficiency of smart quantitative sensation tests.

Authors:  Peter J Dyck; Barbara Argyros; James W Russell; Linde E Gahnstrom; Susan Nalepa; James W Albers; Karen A Lodermeier; Andrew J Zafft; P James B Dyck; Christopher J Klein; William J Litchy; Jenny L Davies; Rickey E Carter; L Joseph Melton
Journal:  Muscle Nerve       Date:  2014-01-28       Impact factor: 3.217

Review 3.  Diabetic neuropathy: mechanisms, emerging treatments, and subtypes.

Authors:  James W Albers; Rodica Pop-Busui
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 4.  Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Authors:  Peter J Dyck; Bruce V Taylor; Jenny L Davies; Michelle L Mauermann; William J Litchy; Christopher J Klein; P James B Dyck
Journal:  Muscle Nerve       Date:  2015-08-13       Impact factor: 3.217

5.  Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Authors:  Peter J Dyck; John C Kincaid; P James B Dyck; Vinay Chaudhry; Namita A Goyal; Christina Alves; Hayet Salhi; Janice F Wiesman; Celine Labeyrie; Jessica Robinson-Papp; Márcio Cardoso; Matilde Laura; Katherine Ruzhansky; Andrea Cortese; Thomas H Brannagan; Julie Khoury; Sami Khella; Márcia Waddington-Cruz; João Ferreira; Annabel K Wang; Marcus V Pinto; Samar S Ayache; Merrill D Benson; John L Berk; Teresa Coelho; Michael Polydefkis; Peter Gorevic; David H Adams; Violaine Plante-Bordeneuve; Carol Whelan; Giampaolo Merlini; Stephen Heitner; Brian M Drachman; Isabel Conceição; Christopher J Klein; Morie A Gertz; Elizabeth J Ackermann; Steven G Hughes; Michelle L Mauermann; Rito Bergemann; Karen A Lodermeier; Jenny L Davies; Rickey E Carter; William J Litchy
Journal:  Muscle Nerve       Date:  2017-04-07       Impact factor: 3.217

6.  Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Phillip A Low; David Robertson; Sid Gilman; Horacio Kaufmann; Wolfgang Singer; Italo Biaggioni; Roy Freeman; Susan Perlman; Robert A Hauser; William Cheshire; Stephanie Lessig; Steven Vernino; Jay Mandrekar; William D Dupont; Thomas Chelimsky; Wendy R Galpern
Journal:  Lancet Neurol       Date:  2014-02-05       Impact factor: 44.182

Review 7.  Glucose control and diabetic neuropathy: lessons from recent large clinical trials.

Authors:  Lynn Ang; Mamta Jaiswal; Catherine Martin; Rodica Pop-Busui
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

Review 8.  Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study.

Authors:  Wolfgang Singer; Phillip A Low
Journal:  Clin Auton Res       Date:  2015-03-13       Impact factor: 4.435

9.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.

Authors:  John L Berk; Ole B Suhr; Laura Obici; Yoshiki Sekijima; Steven R Zeldenrust; Taro Yamashita; Michael A Heneghan; Peter D Gorevic; William J Litchy; Janice F Wiesman; Erik Nordh; Manuel Corato; Alessandro Lozza; Andrea Cortese; Jessica Robinson-Papp; Theodore Colton; Denis V Rybin; Alice B Bisbee; Yukio Ando; Shu-ichi Ikeda; David C Seldin; Giampaolo Merlini; Martha Skinner; Jeffery W Kelly; Peter J Dyck
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

10.  A trial of proficiency of nerve conduction: greater standardization still needed.

Authors:  Peter J Dyck; James W Albers; James Wolfe; Charles F Bolton; Nancy Walsh; Christopher J Klein; Andrew J Zafft; James W Russell; Karen Thomas; Jenny L Davies; Rickey E Carter; L Joseph Melton; William J Litchy
Journal:  Muscle Nerve       Date:  2013-07-17       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.